Skip to main content

Table 1 Patient experience of the ototoxicity monitoring programme

From: Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting

Questions

Responses – n (%)

1. Did you receive information about the ototoxic effects of the chemotherapy medication before commencing with treatment?

No – 33 (41.3)

Yes – 47 (58.8)

2. Who provided you with the information?

Nurse – 3 (6.4%)

Oncologist /clinician– 36 (76.6)

Audiologist – 7 (14.9)

Pharmacist – 0

Radiotherapist – 1 (2.1)

3. Who referred you for ototoxicity monitoring?

Nurse – 3 (3.8)

Oncologist/clinician – 32 (40.0)

Pharmacist – 1 (1.3)

Audiologist – 40 (50)

Radiotherapist – 4 (5)

4. Were the audiological evaluations conducted on the same day as your chemotherapy?

No – 53 (66.3)

Yes – 6 (7.5)

Sometimes – 21 (26.3)

5. Do you feel that the duration of the audiological testing was too long?

No – 38 (47.5)

Yes – 42 (52.5)

6. Were the results of the audiological evaluations clearly explained to you?

No - 0 (0)

Yes – 80 (100.0)

7. Which of the following recommendations were made?

Hearing aid evaluation – 3 (3.8)

Counselling – 46 (57.5)

Tinnitus management – 3 (3.8)

Combination of all - 5 (6.3)

Hearing aid evaluation and counselling – 4 (5.0)

Hearing aid evaluation and tinnitus management – 19 (23.8)

8. Did you follow-up on any of the above recommendations made?

No -1 (1.3)

Yes – 76 (95.0)

Sometimes – 3 (3.8)

9. Do you feel that the monitoring of your hearing during chemotherapy was beneficial

No – 3 (3.8)

Yes – 71 (88.8)

Do not know – 6 (7.5)